Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

50.96 +3.08 (+6.43%)
Streaming Delayed Price Updated: 10:30 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
29 30 Next >
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector. 
Via InvestorPlace
3 Top Healthcare Stocks to Buy for June
These stocks have what it takes to deliver long-term growth. 
Via The Motley Fool
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
Wall Street is at max pessimism with this biotech, which might be a big mistake. 
Via The Motley Fool
3 Disruptors I Love Right Now
These stocks could deliver huge returns as the companies transform the economy. 
Via The Motley Fool
Prediction: These 2 Stocks Could Double In the Next Year
It would be a continuation of solid recent performances. 
Via The Motley Fool
3 No-Brainer Stocks to Buy for Under $100 Right Now
These stocks might not remain under $100 for too much longer. 
Via The Motley Fool
CRISPR Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for CRISPR Therapeutics's Future
Via Benzinga
Is CRISPR Therapeutics Stock a Buy Now?
The clinical-stage biotech company has been on the rise. 
Via The Motley Fool
Is It Too Late to Buy CRISPR Stock?
Five reasons to buy the promising biotech stock now. 
Via The Motley Fool
2 Supercharged Stocks to Buy With $100
These stocks are climbing in the double digits. 
Via The Motley Fool
2 Top Trends to Invest $5,000 in Right Now
Renewable energy and gene-editing medical therapies are poised to grow exponentially. 
Via The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health
Both stocks are recovering after big losses last year. 
Via The Motley Fool
A Good Week For The Market But A Pause In The Biotech Rally
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It
Her investing thesis for holding it is probably the same as ever. 
Via The Motley Fool
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher. 
Via InvestorPlace
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
2 Stocks You'll Be Glad You Bought at These Prices
Bear markets create opportunities to buy high-growth stocks at discounted valuations. 
Via The Motley Fool
2 Soaring Growth Stocks That Could Rocket Even Higher
One of these stocks is up 57% this year, and the other one has more than tripled already. 
Via The Motley Fool
Why These 3 Nasdaq Stocks Were Glowing Green This Week
These three biopharmaceutical stocks rocketed higher this week. 
Via The Motley Fool
Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners said CRISPR Therapeutics AG (NASDAQ: CRSP) reported strong 
Via Benzinga
Why CRISPR Therapeutics Stock Is on Fire Today
Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today. 
Via The Motley Fool
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock
Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets. 
Via The Motley Fool
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May
This market-beating biotech stock still has more room to run. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy in May
You'll want to hold onto these innovative companies for the long term. 
Via The Motley Fool
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
Cathie Wood is loading up on these biotech stocks. 
Via The Motley Fool
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
Why CRISPR Therapeutics Just Became an Even Better Buy
Is this a no-brainer investment to add to your portfolio? 
Via The Motley Fool
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.